Form 8-K Telomir Pharmaceuticals, For: Sep 17

Article Stock Quotes (1)

FREE Breaking News Alerts from StreetInsider.com!

StreetInsider.com Top Tickers, 10/18/2026

1. VRNS
2. JBHT
3. CRWV
4. TSLA
5. SCHW

6. GPRK
7. TFC
8. TRV
9. USB
10. SPY

Top News Most Read Special Reports

September 17, 2026 8:31 AM EDT

E-mail

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the

Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): September 17, 2026

TELOMIR PHARMACEUTICALS, INC.

(Exact Name of Registrant as Specified in its Charter)

Florida	001-41952	87-2606031
(State or Other Jurisdiction	(Commission	(IRS Employer
of Incorporation)	File Number)	Identification No.)

100 SE 2nd St, Suite 2000, #1009

Miami, Florida 33131

(Address of Principal Executive Offices)

Registrant’s telephone number, including area code: (786) 396-6723

Not Applicable

(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

	☐	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

	☐	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

	☐	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

	☐	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class		Trading Symbol		Name of each exchange on which registered
Common Stock, no par value		TELO		The Nasdaq Stock Market LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 7.01 Regulation FD Disclosure.

On September 17, 2026, Telomir Pharmaceuticals, Inc. (the “Company”) issued a press release announcing the publication of a peer-reviewed preclinical study titled “Targeted Intracellular Metal Modulation Attenuates Oxidative Stress and Preserves Retinal Integrity and Function in a Zebrafish Model of Mitochondrial Dysfunction and Age-Related Retinal Degeneration” in International Journal of Molecular Sciences. 2026; 27(18), 8265.

The publication demonstrated that Telomir-Zn restored visual function and retinal structure in a model of age-related macular degeneration (“AMD”). Following 14 days of oral treatment, Telomir-Zn significantly improved multiple measures of visual performance and reduced retinal degeneration, with restoration of thickness across multiple retinal layers. Treatment also reduced mitochondrial oxidative stress and was associated with a dose-dependent increase in relative telomeric DNA content toward the profile observed in healthy animals and restoration of altered DNA methylation patterns at selected aging-associated CpG loci.

Complementary mechanistic studies demonstrated that Telomir-Zn reduced labile intracellular Fe²⁺ while increasing intracellular zinc and potently inhibited multiple Fe²⁺-dependent Jumonji C histone demethylases (“KDMs”), enzymes involved in the epigenetic regulation of gene expression. These findings provide additional evidence supporting a potential relationship between Telomir-Zn’s modulation of intracellular metal homeostasis and metal-dependent epigenetic regulation.

The Company’s clinical development remains focused on oncology, with Telomir-Zn advancing under an FDA-cleared Investigational New Drug application for a Phase 1/2 clinical trial in patients with advanced or metastatic triple-negative breast cancer (“TNBC”). The retinal findings add to the Company’s growing body of published research supporting a common biological framework centered on intracellular metal homeostasis and epigenetic regulation and demonstrate the potential broader relevance of Telomir-Zn’s underlying biology beyond the Company’s current clinical development focus.

Cautionary Note Regarding Forward-Looking Statements

This report contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements generally may be identified by the use of words such as “anticipate,” “expect,” “plan,” “can,” “could,” “would,” “may,” “will,” “believe,” “estimate,” “forecast,” “goal,” “project,” “guidance,” “potential,” “intend,” “seek,” “target” and other words of similar meaning, although not all forward-looking statements include these words. Forward-looking statements may include, but are not limited to, statements regarding the therapeutic potential, mechanism of action, development plans, regulatory pathway, safety profile, efficacy, anticipated clinical development, commercialization prospects, market opportunity and future development of Telomir-Zn, including its potential applications in oncology and other disease indications, and the Company’s other research and development programs.

These forward-looking statements are based on current expectations, estimates, forecasts and projections, as well as management’s current beliefs and assumptions, and are subject to significant risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statements. These risks and uncertainties include, among others, risks related to preclinical and clinical development; the initiation, timing, progress and results of clinical trials and other studies; the ability to recruit and enroll patients in clinical trials; the safety and efficacy of Telomir-Zn; the Company’s ability to obtain and maintain regulatory approvals; the timing and outcome of regulatory submissions and interactions with regulatory authorities; reliance on third-party manufacturers, contract research organizations and other service providers; intellectual property protection; the Company’s ability to obtain additional financing; commercialization and market acceptance of the Company’s product candidates, if approved; competition; market conditions; and the other risks identified under the heading “Risk Factors” contained in the Company’s Annual Report on Form 10-K and the Company’s subsequent filings with the U.S. Securities and Exchange Commission (“SEC”).

Forward-looking statements contained in this report speak only as of the date of this report, and the Company undertakes no obligation to update or revise these forward-looking statements, whether as a result of new information, future events or otherwise, except as required by applicable law.

Investors are cautioned not to place undue reliance on these forward-looking statements. Additional information regarding these and other risks and uncertainties is contained in the Company’s filings with the SEC, including its Annual Report on Form 10-K and subsequent filings, available at www.sec.gov and in the Investors section of the Company’s website at www.telomirpharma.com. Forward-looking statements should be considered in light of these risks and uncertainties.

Item 9.01 Financial Statements and Other Exhibits.

(d) Exhibits.

Exhibit No.		Description
99.1		Press Release of Telomir Pharmaceuticals, Inc., dated September 17, 2026
104		Cover Page Interactive Data File (embedded within the Inline XBRL document)

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.